These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 27324442)

  • 1. ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization.
    Ylä-Herttuala S
    Mol Ther; 2016 Jun; 24(6):1013-1014. PubMed ID: 27324442
    [No Abstract]   [Full Text] [Related]  

  • 2. Investor Outlook: Rising from the Ashes; GSK's European Approval of Strimvelis for ADA-SCID.
    Schimmer J; Breazzano S
    Hum Gene Ther Clin Dev; 2016 Jun; 27(2):57-61. PubMed ID: 27267267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.
    Montiel-Equihua CA; Thrasher AJ; Gaspar HB
    Curr Gene Ther; 2012 Feb; 12(1):57-65. PubMed ID: 22348551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
    Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
    Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for ADA-SCID, the first marketing approval of an
    Aiuti A; Roncarolo MG; Naldini L
    EMBO Mol Med; 2017 Jun; 9(6):737-740. PubMed ID: 28396566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Promising Option for ADA-SCID Patients.
    Am J Med Genet A; 2021 Nov; 185(11):3184-3185. PubMed ID: 34655170
    [No Abstract]   [Full Text] [Related]  

  • 7. EMA greenlights second gene therapy.
    Mullard A
    Nat Rev Drug Discov; 2016 May; 15(5):299. PubMed ID: 27139988
    [No Abstract]   [Full Text] [Related]  

  • 8. Gene therapy's out-of-body experience.
    Scott CT; DeFrancesco L
    Nat Biotechnol; 2016 Jun; 34(6):600-7. PubMed ID: 27281416
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.
    Cooper AR; Lill GR; Shaw K; Carbonaro-Sarracino DA; Davila A; Sokolic R; Candotti F; Pellegrini M; Kohn DB
    Blood; 2017 May; 129(19):2624-2635. PubMed ID: 28351939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising Results with Ex Vivo Lentiviral HSPC Gene Therapy in ADA-SCID.
    Am J Med Genet A; 2021 Aug; 185(8):2291-2292. PubMed ID: 34240545
    [No Abstract]   [Full Text] [Related]  

  • 11. A Journey in the Development of Gene Therapy for Inherited Disorders of the Bone Marrow.
    Kohn D; Wilson JM
    Hum Gene Ther Clin Dev; 2015 Dec; 26(4):203-7. PubMed ID: 26684443
    [No Abstract]   [Full Text] [Related]  

  • 12. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
    Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
    Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.
    Shaw KL; Garabedian E; Mishra S; Barman P; Davila A; Carbonaro D; Shupien S; Silvin C; Geiger S; Nowicki B; Smogorzewska EM; Brown B; Wang X; de Oliveira S; Choi Y; Ikeda A; Terrazas D; Fu PY; Yu A; Fernandez BC; Cooper AR; Engel B; Podsakoff G; Balamurugan A; Anderson S; Muul L; Jagadeesh GJ; Kapoor N; Tse J; Moore TB; Purdy K; Rishi R; Mohan K; Skoda-Smith S; Buchbinder D; Abraham RS; Scharenberg A; Yang OO; Cornetta K; Gjertson D; Hershfield M; Sokolic R; Candotti F; Kohn DB
    J Clin Invest; 2017 May; 127(5):1689-1699. PubMed ID: 28346229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
    Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
    Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety.
    Cicalese MP; Ferrua F; Castagnaro L; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Roncarolo MG; Aiuti A
    Mol Ther; 2018 Mar; 26(3):917-931. PubMed ID: 29433935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
    Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM
    Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.
    Cicalese MP; Ferrua F; Castagnaro L; Pajno R; Barzaghi F; Giannelli S; Dionisio F; Brigida I; Bonopane M; Casiraghi M; Tabucchi A; Carlucci F; Grunebaum E; Adeli M; Bredius RG; Puck JM; Stepensky P; Tezcan I; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Ciceri F; Roncarolo MG; Aiuti A
    Blood; 2016 Jul; 128(1):45-54. PubMed ID: 27129325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ADA gene expression and transduction efficiency in ADA/SCID patients undergoing gene therapy.
    Carlucci F; Tabucchi A; Aiuti A; Rosi F; Floccari F; Pagani R; Marinello E
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1245-8. PubMed ID: 15571238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
    Silver JN; Flotte TR
    Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.